Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

SOPHIE J BAKRI

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1861464455
CMS profile
175630
Location
ROCHESTER, MN

General Payments · PY2018–2024

$201,693.38

  • Reported across 170 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$13,770.83

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $12,785.00 6
Travel and Lodging $469.91 2
Food and Beverage $373.46 4
Gift $142.46 1

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Regeneron Pharmaceuticals, Inc. $5,301.29 6
EyePoint Pharmaceuticals US, Inc. $5,009.93 4
F. Hoffmann-La Roche AG $3,360.00 2
ABBVIE INC. $99.61 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $29,695.47 32
PY2019 $52,791.43 45
PY2020 $10,926.82 10
PY2021 $12,444.75 14
PY2022 $31,334.96 22
PY2023 $50,729.12 34
PY2024 $13,770.83 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $99.61 08/22/2024 Food and Beverage Undisputed 01/23/2026 1103269901 CMS
EyePoint Pharmaceuticals US, Inc. $108.31 01/18/2024 Food and Beverage Undisputed 01/23/2026 1089507084 CMS
EyePoint Pharmaceuticals US, Inc. $4,725.00 10/02/2024 Consulting Fee Undisputed 01/23/2026 1089507292 CMS
EyePoint Pharmaceuticals US, Inc. $142.46 12/05/2024 Gift Undisputed 01/23/2026 1089507004 CMS
EyePoint Pharmaceuticals US, Inc. $34.16 12/07/2024 Food and Beverage Undisputed 01/23/2026 1089507790 CMS
F. Hoffmann-La Roche AG $1,680.00 03/22/2024 Consulting Fee Undisputed 01/23/2026 1133114520 CMS
F. Hoffmann-La Roche AG $1,680.00 08/23/2024 Consulting Fee Undisputed 01/23/2026 1133114524 CMS
Regeneron Pharmaceuticals, Inc. $940.00 01/08/2024 Consulting Fee Undisputed 01/23/2026 1114396318 CMS
Regeneron Pharmaceuticals, Inc. $940.00 10/10/2024 Consulting Fee Undisputed 01/23/2026 1114396320 CMS
Regeneron Pharmaceuticals, Inc. $131.38 10/14/2024 Food and Beverage Undisputed 01/23/2026 1114396322 CMS
Regeneron Pharmaceuticals, Inc. $2,820.00 12/13/2024 Consulting Fee Undisputed 01/23/2026 1114396324 CMS
Regeneron Pharmaceuticals, Inc. $16.75 12/13/2024 Travel and Lodging Undisputed 01/23/2026 1114396326 CMS
Regeneron Pharmaceuticals, Inc. $453.16 12/13/2024 Travel and Lodging Undisputed 01/23/2026 1114396328 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.